Will the Dallas Cowboys beat the Tampa Bay Buccaneers at home on October 9, 2026?

Market (Kalshi) prices Dallas as a solid favorite (~69-77% implied, trending up to 0.77 by game week), and the underlying team-level data are consistent with that direction (DAL win-rate and margin series run several points better than TB's), but the home-field effect itself is statistically indistinguishable from zero in this sample, so most of the edge has to come from team quality/injury differentials rather than home field per se.

Own objection: The injury series (d7/d8) are only proxy counts, not position-weighted severity — a rising 'questionable' count from 2 to 5 over 2026-10-01 to 2026-10-04 could reflect minor/precautionary listings (e.g., vets resting ankle/wrist issues) rather than game-changing absences, and if the market moved from 0.66 to 0.77 mostly on illiquid Kalshi order-flow rather than confirmed starter-level injury news (e.g., a TB skill-position starter ruled out), then 0.77 is an overreaction and the true probability is closer to the 0.66-0.69 range seen earlier in the week — which would make the 'edge' versus market closer to zero, not a mispricing in DAL's favor.

Market pricing (d1) and the point-spread/win-probability data (d7, d8, d2) jointly indicate Dallas is a substantial underdog at home against Tampa Bay, and an in-sample regression finds no significant home-field edge for Dallas this season - so the base-rate home-win advantage is overridden by team-specific information embedded in the market price.

Own objection: d1 and d2 may not both reference the DAL-win contract for this specific game - d2's older, shorter series (n=9, ending 2026-09-29, values 0.66-0.77) could itself be the actual DAL-win price, in which case my reading is inverted and Dallas is the ~69-77% favorite, not the ~20% underdog; ticker/series identity is not explicitly confirmed in the data handles, which is a material labeling risk to this whole estimate.

The price history (d1, d2, and the widening spread proxies d5/d6) is consistent with Dallas being a moderately strong, increasingly confident home favorite (market-implied ~0.70-0.80), roughly in line with or slightly above the historical base rate for a ~5-6 point home favorite (~0.70). Because the implied probability has been flat and tightly clustered for several days (d2's sd=0.034 across 118 prints), the market looks largely settled rather than reactive, meaning a fundamentally correct "Dallas wins" view likely has limited incremental edge at current prices — most of the thesis is already priced in. The unexplained collapse in d4's last two prints is the main wildcard, but given it diverges from the more stable d1/d2 signal and the weak d3-d4 correlation (s5), I weight it as probable noise rather than a genuine late repricing.

Own objection: The data series are not unambiguously labeled, so my mapping of d1/d2 to "Dallas implied probability" and "TB implied probability" is an inference, not an observed fact. If d2 is actually a different market (e.g., a prop or the DAL-side price itself, not TB's complement), the market-implied DAL probability could be far lower (~0.20-0.35, matching d3's recent 0.265-0.425 band), which would flip the positioning read entirely — the market could be pricing Dallas as an underdog or near-coinflip, not a strong favorite. The late-week collapse in d4 to 0.005-0.115 on 10/4 is also unexplained and could reflect real news (e.g., a Dallas injury) that moved a thin market sharply against the home team just before the window closes, which I cannot rule out given no injury/lineup data was supplied.

The data provided does not establish a reliable causal basis for predicting the Oct 9, 2026 Dallas-Tampa Bay outcome: the one 'significant' correlation (s3) is almost certainly inflated by near-unit autocorrelation, the influence test (s4) shows the underlying feature has weak/near-zero robust predictive power, and the identity/meaning of several series (d1, d3, d4, d6-d8) is not confirmed by metadata, creating serious labeling and reverse-causality risk. Absent a verified causal signal, I default close to the NFL home-field base rate, nudged slightly upward only if d8 is indeed a spread favoring Dallas, while flagging that this interpretation is unverified.

Own objection: If d8 really is the current Vegas/Kalshi-implied spread (Dallas favored by ~5-6 at home) and d6/d7 are live market win probabilities converging around 0.42/0.20 (implying DAL far above TB), markets aggregate far more information (injuries, recent form, matchup-specific data) than any of my causal critiques can touch — in which case the efficient-market prior alone (back out ~60-65% DAL win probability from a 5.5-point line) should dominate, and my skepticism about labeling/autocorrelation, while methodologically valid, may be overcorrecting against a perfectly good signal that I'm simply failing to recognize due to poor metadata.

• to Analyst Bfactual 0.8B reads d1 (n=118, clustered 0.175-0.20) as the DAL-win contract itself, implying DAL is a ~20% underdog. I read the comparable early-week Kalshi series (my d6, n=9, 0.66-0.77 trending to 0.77) as the DAL-win contract, implying DAL is a ~69-77% favorite. These are directly opposite readings of market direction for the same game. B even flags this exact labeling risk as their own objection, so this is a live, unresolved factual dispute about series identity, not just a difference in judgment.
• to Analyst Bmethodological 0.6B's spread-to-win-probability mapping (d7, ~5-6 pts favoring TB) is only valid if their identification of the favored team in d7 is correct; if d1/d7 labels are reversed (as I believe), the derived ~70-75% TB win probability actually belongs to DAL. I don't trust the spread-sign inference without an explicit 'favorite' field.
• to Analyst Cassumption 0.3C anchors the base rate on a remembered 2015-2025 league-wide rate for 5-7pt home favorites (0.70) and effectively treats the market as near that base rate already, i.e., little edge left. I anchor the base rate on how efficiently markets price favorites in the 60-70% implied range historically (0.58) and treat team-quality/injury differentials, not home field, as the main driver. These are different base-rate construction philosophies that happen to point to similar numbers, but C's reasoning leans on an unverified historical memory figure rather than a test run on this dataset.
• to Analyst Cinterpretation 0.3C treats the late-week movement/dispersion in the data (d4 collapse, weak d3-d4 correlation) as 'probable noise,' concluding the market is largely settled with limited incremental edge. I instead treat the rising injuries_questionable count (my d8, 2→5 over Oct 1-4) as a live, not-yet-fully-priced input, and argue most of the edge over the market line should come from injury/team-quality differentials still being absorbed — i.e., I see more remaining uncertainty/edge potential than C does, from the same underlying noisy series.
• to Analyst Dmethodological 0.5D defaults close to the pure home-field base rate (0.57) because the specific regressions/correlations tested (s3, s4) show weak or spurious causal signal, and treats this as grounds to discount the market price almost entirely absent 'verified causal signal.' I disagree with requiring a causal regression result before trusting the market-implied probability: markets aggregate injury/form/matchup information that a simple 24-46 game OLS or correlation test on this limited series was never going to detect well, so the absence of a significant in-sample regression result is weak evidence against the market price, not strong evidence for ignoring it.
• to Analyst Dinterpretation 0.3D's own objection acknowledges that if d8 is really a Dallas-favoring spread and d6/d7 are DAL/TB win probabilities near 0.42/0.20, the efficient-market prior should dominate and imply ~60-65% DAL — which is actually fairly close to my own estimate's direction and base-rate-adjusted range. D chooses to weight their labeling skepticism more heavily than this alternative reading; I weight the market-direction evidence (my d6, Kalshi 0.66-0.77 trending to 0.77) more heavily given it is a less ambiguous series identity than the ones D is skeptical of.
• Same evidence as another seat: Early-week Kalshi DAL-win implied probability series (n=9, 2026-09-29, values clustering 0.66-0.77, mean ~0.69) — used as my d6, Analyst C's d1, and referenced/contested as part of Analyst B's d1/d2 identity dispute.; OLS-HAC regression testing beta[is_home] for statistical significance on a Dallas-related outcome series (my s5, p=0.775; Analyst B's s4, p=0.245) — same test family (HAC-robust home-field effect regression), applied to possibly different dependent variables (win/margin), both concluding home-field effect is not statistically significant this season.

• to Analyst Ainterpretation 0.8Analyst A reads d6 (0.66-0.77, trending up to 0.77) as the Kalshi DAL-win price and concludes Dallas is a strong favorite. My own series d1 (n=118, clustered 0.175-0.20) is a different, much larger and more stable series that I read as the DAL-win price itself, implying Dallas is a ~20% underdog, not a 70%+ favorite. We cannot both be right about which series is the actual game contract price; this is a direct factual/labeling contradiction, not just a different gloss on the same facts.
• to Analyst Amethodological 0.3Analyst A's home-field regression (s5: beta=1.33, p=0.775, n=24) and my own (s4: beta=-5.09, p=0.245, n unspecified but implied larger) both find no significant home effect, but use different sample sizes and point estimates of opposite sign. Neither of us can claim a precise effect size with such wide, overlapping-zero CIs; treating either point estimate as informative (rather than 'no detectable effect') is an overreach on both sides.
• to Analyst Binterpretation 0.0This is my own thesis as stated in the prompt (labeled Analyst B here is actually my own view restated) -- no disagreement with self.
• to Analyst Cinterpretation 0.8Analyst C interprets d2 (n=118, stable at 0.195) as the complementary TB-side price, implying DAL~0.80, i.e., the exact opposite directional conclusion I draw from what appears to be the same or a very similar underlying series (my d1 vs their d2, both n=118, clustered near 0.175-0.20). We are very likely looking at the same raw series and drawing opposite conclusions about which side of the contract it represents -- this is the single largest unresolved ambiguity in the whole committee's evidence base.
• to Analyst Cmethodological 0.3Analyst C treats a 0.70 'historical home favorite by 5-6 points' base rate as a soft anchor without running a HAC or out-of-sample test of that specific conditional base rate on current data, instead relying on a recalled historical range. I prefer deriving a base rate from the sample actually in hand (or flagging that we lack a direct conditional base-rate test) rather than importing an external, untested 68-72% figure.
• to Analyst Dmethodological 0.5Analyst D's s3/s4 critique (near-unit autocorrelation inflating apparent significance, effective N near 1-2) is a materially stronger and more rigorous caution than anything I ran myself -- I did not test for autocorrelation-inflated effective sample size in my own d1 series (autocorr_1=0.943, explicitly noted by me), so D's critique actually applies directly to my own evidence d1 and I should weight my own point estimate from d1 down accordingly. This is a point I underweighted, not a disagreement with D's math, but with D's overall 'default to base rate' conclusion.
• to Analyst Dassumption 0.5Analyst D treats the entity/labeling ambiguity as grounds to default almost entirely to the unconditional home-field base rate (0.57-0.58), discarding most market information. I think even with labeling ambiguity, the directional information that SOME series clustered near 0.175-0.20 for 118 stable observations (d1/d2, mine and C's) represents a real, converged market price for one side of this specific game, and should not be discarded entirely -- the question is which side, not whether the number means anything.
• Same evidence as another seat: d1 (Analyst B's own) is very likely the same raw series as Analyst C's d2: both n=118, both stable/clustered near 0.175-0.20, both spanning through 2026-10-03/10-04 -- this is almost certainly duplicated evidence, not independent confirmation, despite opposite interpretations of which side it represents.; The home-field HAC regression result (my s4: beta=-5.09, p=0.245) and Analyst A's s5 (beta=1.33, p=0.775) are run on overlapping or related underlying game-log data (Dallas home/away margins) and both arrive at 'no significant home effect' -- these should be treated as one piece of evidence (no detectable home-field edge), not two independent confirmations.; Analyst D's s3 (correlation=0.50 between two market-derived series, autocorrelation=0.98) and my own flagged concern about d1's autocorr_1=0.943 are diagnosing the same underlying statistical artifact (near-unit-root market price series inflating apparent significance) and should not be counted as two separate findings.

• to Analyst Aassumption 0.3A sets base rate at 0.58, blending 'home favorites in 60-70% implied tier' with a separate home-field insignificance finding, whereas I anchor base rate at 0.70 for a 5-6 point home favorite specifically. A's base rate conflates market calibration at a price tier with a different unconditional home-field stat, which understates the historical hit rate for favorites of this size.
• to Analyst Ainterpretation 0.3A treats the home-field OLS insignificance (beta=1.33, p=0.775) as meaningfully undercutting the YES case, while I treat it as irrelevant to a market-implied-probability read — the market price already embeds whatever home-field effect exists (or doesn't); a null home-field coefficient doesn't contradict a market-derived 0.70-0.80 estimate.
• to Analyst Bfactual 0.8B reads d1 (n=118, clustered 0.175-0.20) as the DAL-win contract itself, implying Dallas is a ~20% underdog, whereas I read the functionally identical series (my d2) as the complementary/TB side, implying Dallas ~0.80. This is a direct, mutually exclusive factual disagreement about what the same raw series represents — one of us is inverted.
• to Analyst Bassumption 0.7B assumes d7 (point spread ~5-6) favors Tampa Bay (the away team), while I (via d5/d6, a different but analogous spread-like series) read the widening 2→5/5→6 trend as favoring Dallas (the home team). Same magnitude, opposite team assignment.
• to Analyst Dmethodological 0.5D defaults to the generic base rate (0.57) due to labeling/autocorrelation concerns across nearly all series, effectively discarding the market-price evidence (d1/d2 in my labeling) as unusable. I treat the tightly clustered, high-n, low-variance d2 series as a legitimate (if unconfirmed) market-settlement signal worth anchoring to, not something to discard wholesale — full skepticism here throws out the most informative data we have.
• to Analyst Dinterpretation 0.3D flags s3's 0.50 correlation as spurious due to autocorrelation and generalizes this caution to undermine confidence in market-derived series broadly; I apply a narrower, series-specific skepticism (e.g., discounting d3/d4 as noise) while still trusting the stable d1/d2 cluster as the primary signal.
• Same evidence as another seat: My d1 (9 obs, 0.66-0.77, 2026-09-29) appears to be the same underlying series as Analyst A's d6.; My d2 (118 obs, clustered ~0.195, through 10/3-10/4) appears to be the same underlying series as Analyst B's d1 — we assign opposite team identities to it.; The weak/noisy d3-d4 relationship I flag as low-reliability overlaps with Analyst D's s3/s4 concerns about autocorrelation-inflated correlations in large series.

• to Analyst Aassumption 0.5A asserts d1/d3/d2/d4 map cleanly to DAL-own and TB-own win/margin series 'based on series ordering and naming convention,' but admits the handles don't disambiguate which team d7/d8 (injuries) belong to. This is the same unverified-labeling problem I flagged for d1/d3/d4/d6-d8 — A is treating an assumption as near-fact when building the 'team quality differential' narrative.
• to Analyst Amethodological 0.4A's own s5 (OLS-HAC, beta[is_home]=1.33, p=0.775) shows home-field is indistinguishable from zero, which actually supports my skepticism, yet A still leans on market level (0.69-0.77) as if it were a clean, well-identified causal signal rather than a potentially autocorrelated/confounded price series (same autocorrelation concern as my s3 critique, just unexamined by A).
• to Analyst Ainterpretation 0.3A interprets the Kalshi drift from 0.66 to 0.77 as information-driven market movement, but offers no test ruling out thin-liquidity order-flow noise versus genuine news — A's own objection admits this, so A's headline estimate (0.58, anchored near market mean) does not fully discount for this uncertainty the way the stated base rate suggests it should.
• to Analyst Bfactual 0.8B reads d1 (autocorr 0.943, clustered 0.175-0.20) as the DAL-win price implying DAL is a ~20% underdog, directly contradicting A's and C's reading of similar-looking series as DAL being a 0.69-0.80 favorite. These cannot both be right — this is a direct identification conflict on what the raw data represents, not just a difference in interpretation of agreed facts.
• to Analyst Bassumption 0.6B's own objection correctly flags that ticker identity between d1/d2 is unconfirmed and could be inverted, yet B still builds a 'substantial underdog' thesis and base-rate override around this unverified labeling, which is precisely the labeling/reverse-causality risk I raised for d1/d3/d4/d6-d8 — B's confidence is not supported by the metadata any more than mine is undermined by it.
• to Analyst Bmethodological 0.4B's s4 (OLS-HAC home-field effect on margin, p=0.245, negative point estimate) is used to argue home-field is overridden by market info, but a non-significant negative coefficient in a small, likely autocorrelated sample is equally consistent with simply underpowered estimation (same effective-sample-size problem I raised in s3) — B treats a null result as informative evidence against home-field rather than as inconclusive.
• to Analyst Cassumption 0.5C infers d2 is the complementary TB-side price implying DAL~0.80, explicitly flagging this is an inference not a labeled fact — same core labeling uncertainty I raised. C's headline base rate (0.70) and estimate lean heavily on this unverified mapping.
• to Analyst Cfactual 0.3C's own s5 shows d3/d4 correlate only weakly (0.108) and flags autocorrelation-inflated p-values — effectively replicating my s3 finding (0.50 correlation driven by autocorrelation) on a different series pair, reinforcing that these market-derived series as a group do not reliably cohere into one clean signal, which C acknowledges but then substantially discounts (treating d4's collapse as 'probable noise') without a formal test (e.g., placebo/random-date comparison) to support that call.
• to Analyst Cmethodological 0.4C treats the extremely low variance/flatness of d2 (sd=0.034 across 118 prints, autocorr near 1 per B's d1 reading) as evidence the market is 'settled' and information-rich, but low variance with near-unit autocorrelation is exactly the signature of a stale or illiquid series, not necessarily a converged efficient-market consensus — this is the same autocorrelation-as-pseudo-certainty issue I raised in s3.
• to Analyst Dinterpretation 0.0No disagreement — this is my own stated position; included for committee completeness only.
• Same evidence as another seat: s3 (0.50 correlation, p=6.85e-09, autocorr_1=0.98) overlaps conceptually with Analyst C's s5 (weak 0.108 correlation, autocorrelation-inflated p=0.042) and Analyst B's d1 (autocorr_1=0.943) — all three are instances of the same underlying autocorrelation-inflates-significance artifact in these market-derived series.; s4 (leave-one-out influence test showing near-zero robust predictive power, -0.176 correlation, zero sign flips) addresses the same underlying question as Analyst A's s5 and Analyst B's s4 (both OLS-HAC tests finding home-field/is_home effects statistically indistinguishable from zero) — all point to the same null finding on home-field advantage from different angles.

To: Analyst B's challenge (severity 0.8): B claims their series d1 (n=118, clustered 0.175-0.20) is the actual Kalshi DAL-win contract price, implying DAL is a ~20% underdog — directly contradicting my reading of d6 (0.66-0.77) as the DAL-win price implying DAL is a 70%+ favorite.

This is a genuine, severe problem and I cannot resolve it from the data I was given — I don't have ticker-level metadata (series ID -> contract description mapping) to independently verify which handle is the DAL-win leg versus the TB-win leg or some other contract (e.g., a spread/total market, or the opposing team's contract priced at its complement). Two observations push me to think my reading is MORE likely correct, but I concede I cannot prove it: (1) 0.66-0.77 is internally consistent with my team-level margin/win-rate series showing DAL ahead of TB by several points, and with DAL being the home team (home teams are favored more often than not even if home-field itself isn't statistically significant in isolation); 0.175-0.20 would require DAL to be a massive home underdog, which is a much stronger and rarer claim that needs more support than series-ordering convention. (2) My series shows a trend toward DAL (0.66->0.77) as the week progresses toward kickoff, consistent with late injury news typically favoring the home/healthier team; if B's series is the true DAL price, DAL would be drifting toward being an even bigger underdog, which is a coherent but unverified alternative story. But — I was INFERRING the label from naming convention, not OBSERVING a confirmed contract spec, so B's challenge is valid as an identification problem, not just a difference in gloss. I am lowering my confidence in the 0.58 base-rate-to-estimate update accordingly, and I should not report a point estimate above ~0.65 until this is resolved.

Concedes. Would change my mind: A ticker/contract-spec lookup (or raw API metadata) that confirms which series handle corresponds to ticker KXNFLGAME-26OCT08TBDAL-DAL versus the TB leg or another market type. If B's series (0.175-0.20) is confirmed as the actual DAL-win contract price, I fully retract my directional thesis and flip to treating Dallas as a ~20% probability (market-implied) underdog — the entire 'team quality favors DAL' framing would need to be rebuilt from scratch, and I would revise my estimate toward 0.20-0.25 pending any injury-news update. Absent that confirmation, I will not publish a point probability above the lower bound of my own series (0.66) until the labeling ambiguity is resolved.

To: The convergent challenge from A, C, and D: three analysts independently read superficially similar 0-1 bounded series and arrived at mutually exclusive identifications of which side (DAL-win vs. TB-win/complement) d1 represents — my 0.175-0.20 reading vs. their 0.66-0.80 reading for what may be the same underlying contract.

I cannot win this on priors or narrative, and I won't try. The fact that three independent analysts (A, C, D) converge on the opposite identification, while only I read it as DAL-underdog, is itself evidence against my reading — base rate for "1 of 4 analysts is wrong about a factual label" is higher than "3 of 4 are wrong," especially when I already flagged this exact risk unprompted as my own objection before seeing their challenges. That self-flagging shows the uncertainty was real, not manufactured post hoc. I do not have an independent way to re-verify the Kalshi ticker-to-series mapping from here (no tool call available in this response to pull fresh contract metadata), so I cannot adjudicate this with data right now — I can only weigh analyst consensus as a prior over two mutually exclusive hypotheses. Given 3-vs-1, I update my belief that P(d1 = DAL-win price, Dallas ~20% favorite-equivalent underdog) drops from whatever confidence I implicitly held to roughly 0.25, and P(d1 is the complement/TB-side series, Dallas ~70-80% implied) rises to roughly 0.75. This flips my point estimate: if Dallas is actually priced as the 70-80% side, that's directionally consistent with the raw 0.57 home-favorite base rate, and combined with s4's statistically insignificant home-field effect (p=0.245, CI crossing zero) — which doesn't override a market price either direction — the market-implied estimate should dominate once identity is resolved.

Concedes. Would change my mind: A single deterministic check of the Kalshi ticker metadata for KXNFLGAME-26OCT08TBDAL-DAL (which side "DAL" denotes in the YES contract, confirmed via the market's rules/outcome description field, not inferred from price trend) resolves this outright. Absent that, a convergence test: pull both d1 and the A/C/D candidate series together and check whether they sum to ~1.0 at matching timestamps — if d1(t) + d6_or_d2(t) ≈ 1 for overlapping t, they are complements of the same event and the labeling question reduces to which one is tagged DAL vs. TB, which I'd then defer to majority analyst read (3-1) unless I can independently confirm the ticker's outcome field. Until resolved, I retract my point estimate of ~20% and treat P(DAL wins) as bimodal/unresolved, with a provisional lean toward the base rate (0.57) adjusted toward the 3-analyst consensus reading (~0.70-0.80), i.e., a revised point estimate near 0.65-0.70 pending confirmation, falsified if the confirmed ticker metadata shows d1 was correct all along (DAL priced ~0.175-0.20).

To: Analyst B (severity 0.85): B's d1 and my d2 appear to be the same underlying series (both n=118, clustered ~0.175-0.20), yet we assign opposite labels — B reads it as the DAL-side price (implying DAL~0.18-0.20, a significant underdog), I read it as the TB-side complement (implying DAL~0.80, a strong favorite). This is a direct, unresolved contradiction in the single most load-bearing data point for my positioning thesis.

I partially concede the ambiguity is real and material, but I do not concede B's directional read is more likely correct than mine on priors alone — neither of us has a labeled schema, so series-identity is a coin-flip without more metadata. I can still update on indirect evidence: my d1 (n=9, early-week, clustered 0.66-0.77) is a separate, smaller series I interpret as an early DAL-implied probability consistent with a moderate home favorite, the historically expected direction for a Dallas home game against Tampa Bay with no injury/roster data suggesting Dallas is an underdog. If B's labeling is correct, Dallas would be a ~4:1 underdog at home, a far larger and more surprising repricing than the base rate, d1, or d5/d6 (point-spread proxies trending toward Dallas, 2→5, 5→6) would predict. So while I can't rule out B's labeling, the weight of the other series is more consistent with my reading. I lower confidence in the 0.70-0.80 estimate but do not flip it to B's implied ~0.20.

Concedes. Would change my mind: Any of: (1) a labeled schema confirming which side of the Kalshi KXNFLGAME-26OCT08TBDAL-DAL contract d2/B's d1 represents; (2) direct observation of the Kalshi DAL-YES last trade/order book between now and kickoff — below 0.50 would confirm Dallas priced as underdog/coinflip and reverse my thesis; (3) corroborating sportsbook moneyline/spread data showing TB favored or DAL favored by under ~3 points, resolving the ambiguity independently of the disputed series.

To: Combined challenge from A, B, and C: that I over-weighted the absence of a clean causal regression result (s3/s4) as grounds to discard market-derived series (d1/d2/d6-d8) almost entirely, defaulting to the generic 0.57 base rate.

I partially concede the framing error but not the full conclusion. My original position implicitly demanded that a market-implied signal prove itself via in-sample OLS/correlation significance before I'd trust it — that's backwards. Market prices aggregate information (injuries, matchup, recent form) through a mechanism (participants with capital at risk) that doesn't need to show up as a significant coefficient in a 46-118 observation regression to be informative; absence of regression significance is weak evidence against the market price, as A correctly notes, not strong evidence for ignoring it. B and C are also right that three independent analysts converging on similar readings of d1/d2/d6-d8 (tight clustering near 0.175-0.20, bounded 0-1 series read as win probabilities) is itself a form of validation — it's much less likely that three people independently mislabel the same series the same way than that the series actually carries the meaning we're converging on. So I move off a near-pure base-rate default. What I do NOT concede: the s3/s4 autocorrelation and influence-test critique stands on its own technical merits (B agrees it's correct), and it still means I cannot point to s3/s4 as 'verified causal evidence' — I was wrong to use that as the reason to discard the market signal, but the signal's own internal validity problem (near-unit-root autocorrelation collapsing effective N) is real regardless of why I invoked it. Separately, the entity/direction ambiguity (is d8 DAL-favoring or TB-favoring? which team is d1/d3/d4's binary outcome for?) is not resolved by cross-analyst convergence on rough shape — all three of us could be independently anchoring on the same superficial cue (which series is 'home team' labeled first, or scale proximity to 0.5) and be collectively wrong about direction. Convergence on 'this is probably a market signal' is good evidence; convergence on 'it favors Dallas specifically' needs an actual metadata check, not consensus among analysts working from the same ambiguous labels.

Concedes. Would change my mind: (1) Direct metadata/source confirmation that d8 is a Vegas/Kalshi spread with sign convention stated (negative = home favorite) and that it favors Dallas, not Tampa Bay — this alone would let me back out an implied win probability and abandon the base-rate default almost entirely. (2) A placebo test showing d6/d7 (or whichever series is claimed as win-probability) correctly predicts outcomes in a held-out set of other games where the true label IS known/verifiable, confirming the series behaves like real market probabilities rather than some unrelated index. (3) Re-running s3 with first-differenced or detrended series to show the 0.50 correlation survives after removing the near-unit-root component — if it does, I'd substantially raise my confidence the signal is real rather than spurious trend-following. Any one of these converts my estimate from ~0.58-0.60 (modest nudge off 0.57) to something closer to the market-implied 0.60-0.65 range B and C are suggesting.

• +0.05 B's own rebuttal: updates P(d1 = DAL-win price, i.e., Dallas priced as ~20% underdog) down to 0.25 and P(d1 is the complement/TB-side, Dallas ~70-80% favorite) up to 0.75, based on 3-of-4 analyst convergence on the opposite reading. (Analyst B)
• +0.03 C's base rate: home favorites in the ~5-7 point range win straight-up ~68-72% historically (2015-2025), which is materially higher than my blended 0.58 base rate and is consistent with the market-implied 0.69-0.77 DAL read if that identification is correct. (Analyst C)
• +0.02 D's rebuttal conceding that absence of in-sample regression significance (s3/s4) is weak evidence against a market price, not strong evidence for discarding it — moves the group off a near-pure base-rate default toward trusting the market-implied signal. (Analyst D)
• -0.01 D's standing (non-conceded) point that cross-analyst convergence on 'this is a market signal favoring the home team' could still reflect a shared anchoring error on the same ambiguous labels, not independent verification — this keeps identification risk real and caps how far I move. (Analyst D)

BASE RATE: I started from 0.58, a blend of (a) NFL home favorites in the ~60-70% market-implied tier winning close to their implied rate, and (b) this sample's home-field OLS coefficient being statistically indistinguishable from zero (beta=1.33, p=0.775). My own rebuttal already flagged that I could not independently verify, from tool-level metadata, which Kalshi series handle corresponds to the DAL-win leg versus the TB-win leg or complement — this was a genuine identification problem, not just a labeling preference, and I said I should not report above ~0.65 until it was resolved. What changed my mind: this round, three of four analysts (A=me, C, and now D after conceding) converge on reading the clustered, low-autocorrelation-adjusted series near 0.69-0.80 as Dallas's own implied win probability, consistent with Dallas as a ~5-6 point home favorite. Critically, Analyst B — the one holdout who had read the series as Dallas being a ~20% underdog — explicitly conceded the ambiguity and reallocated probability mass (0.75) toward the complement/TB-side interpretation, citing the same convergence logic. B's concession is the single most informative new piece of evidence here: it is a Bayesian update from someone with no stake in matching the majority, explicitly reasoning that "1 of 4 analysts wrong about a factual label" is more likely than "3 of 4 wrong." That doesn't resolve the identification problem with certainty (D is right that convergence on shared, ambiguous metadata is not independent verification), but it meaningfully raises my confidence that 0.69-0.80 is the correct reading, not 0.175-0.20. C's cited base rate for 5-6 point home favorites (0.68-0.72) is also new information I hadn't incorporated — my own base rate (0.58) was more conservative because it heavily weighted the statistically-insignificant home-field coefficient in-sample. C's base rate is a better-matched external reference class (point-spread-conditioned, not generic home-field), and it's consistent with — not contradicted by — the fact that home-field-alone showed no effect in this specific 24-46 game sample, since the market price already encodes team-quality/injury information beyond generic home-field. D's conceded rebuttal (that absence of regression significance is weak evidence against trusting a market price, since markets aggregate information OLS on a small sample can't capture) also supports moving toward the market-implied number rather than anchoring on my base-rate blend. I am NOT fully resolving to C's 0.70-0.80 point estimate, because: (1) the underlying ticker-to-series metadata problem is still unverified by any tool call — this remains analyst consensus, not confirmed data; (2) D's standing objection that shared anchoring across analysts isn't independent evidence is unaddressed; (3) there are still 4 days between the last observed data point (2026-10-04) and kickoff (2026-10-09) during which injury news (e.g., a confirmed starter ruled out) could move the true line, and I have zero data covering that window. I land at 0.67 — meaningfully above my prior 0.58, reflecting the weight ofB's concession and C's base rate, but still short of the 0.70-0.77 market print, reflecting residual identification risk and the unobserved pre-kickoff news window. FALSIFIED IF: the Kalshi KXNFLGAME-26OCT08TBDAL-DAL contract (confirmed via verified ticker metadata, not inferred from series ordering) trades below 0.55 at any point between 2026-10-06 and kickoff (2026-10-09, ~1:00 PM ET), or a confirmed Dallas starter (QB, top WR, or top pass rusher) is ruled OUT with no Tampa Bay starter-level injury offsetting it. If either condition holds, revise toward 0.55 or below.

• +0.20 d6: Kalshi-implied DAL win probability trending 0.66->0.77 over the week of 9/29, read as the DAL-side price moving toward DAL as a favorite (not the TB-side). (Analyst A)
• +0.15 d2: n=118 stable 0.195 print interpreted as the complementary (TB) side of a two-sided binary market, implying DAL ~0.80 on the same system; consistent with historical base rate for ~5-6pt home favorites (~0.68-0.72). (Analyst C)
• +0.05 Rebuttal argument that 3-of-4 analysts independently converging on 'DAL is the favorite' direction is weak-but-real evidence against my own reversed labeling, tempered by D's counter-point that shared anchoring on the same ambiguous labels could produce correlated error rather than independent confirmation. (Analyst D)

BASE RATE: Unconditional NFL home-team win rate ~0.57; home favorites in the 5-7 point range win straight-up ~0.68-0.72 (Analyst C, unverified from-memory figure, not tool-confirmed). My original thesis treated d1 as the literal DAL-win contract price (~0.175-0.20), making Dallas a ~20% underdog despite home-field status, supported by an in-sample finding that home-field has no significant effect on Dallas's margin this season (s4: beta=-5.09, p=0.245, CI crosses zero — this remains valid on its own terms but is orthogonal to the labeling question). The decisive new information is not a new tool run but the *distribution of independent reads* across three other analysts (A, C, D), all of whom, working from the same ambiguous, unlabeled series, converged on the opposite direction: Dallas priced as a 0.66-0.80 favorite, not a 0.175-0.20 underdog. I already flagged this exact identification risk as my own unprompted objection before seeing their work, which is evidence the ambiguity is real rather than something I'm rationalizing post hoc. I cannot independently verify the Kalshi ticker-to-series mapping from here (no tool call available to pull contract metadata in this turn), so I am updating on analyst-convergence as a weak Bayesian prior over two mutually exclusive labeling hypotheses, not on any new deterministic test. P(my reading correct) drops to ~0.25; P(the complement reading — DAL is the 0.70-0.80 favorite — correct) rises to ~0.75. Blending: 0.25×0.20 + 0.75×0.70 ≈ 0.59, which I round to 0.60. I do NOT fully adopt Analyst C's 0.80 or A's 0.77 point estimate, for two reasons that remain UNRESOLVED and UNCERTAIN: (1) Analyst D's correct technical point that s3's headline correlation (0.50, p=6.85e-09) is likely spurious due to near-unit-root autocorrelation (lag-1=0.98), meaning the "three independent analysts agree" framing overstates true independence — all three may be anchoring on the same superficial cue (series ordering, scale proximity to 0.5) rather than verifying ticker identity; (2) no analyst, including me, has actual metadata confirming which series is the DAL-win contract for this specific game versus some other market. This residual ambiguity caps my confidence at 0.45 and keeps my point estimate below the 0.70-0.80 range the market-believers propose. FALSIFICATION CONDITION (updated): If the Kalshi KXNFLGAME-26OCT08TBDAL-DAL contract is observed trading below 0.45 for DAL at any point between 2026-10-06 and kickoff, or if post-game/post-hoc metadata inspection confirms d1 (not d2/d6) was in fact the DAL-win price all along, this revised 0.60 estimate is falsified and should revert toward my original ~0.20-0.25 reading.

• +0.00 s5: OLS-HAC home-field beta=1.33, CI=[-7.8,10.45], p=0.775 — generic home-field effect is statistically indistinguishable from zero in-sample (Analyst A)
• +0.02 Rebuttal quantifying belief update: P(d1=TB-side/complement, i.e. Dallas is the 0.70-0.80 favorite) rises to ~0.75 after weighing 3-of-4 analyst convergence on that labeling (Analyst B)
• +0.01 d7: point-spread-magnitude series (n=13, mean 5.08, last obs=6) consistent with a ~5-6 point line magnitude, matching the scale of my own d5/d6 spread-widening proxy (2→5, 5→6) and standard spread-to-win-prob mapping (~70-75%) (Analyst B)
• -0.01 s3: headline 0.50 correlation between two market-derived series has lag-1 autocorrelation 0.98, effective N≈1-2, meaning the apparent 'three analysts independently converge' validation is weaker than it looks — convergence could reflect shared superficial anchoring on scale/ordering rather than independent confirmation (Analyst D)
• +0.00 d8/d7 injury-count series rising 2→5 for the team A infers is the opponent, flagged as possibly minor/precautionary rather than starter-level — weak, non-decisive corroboration of Dallas-favorable drift (Analyst A)

Net movement is small (+0.02) and stays within my original 0.70-0.80 band. The main new information is not a probability-moving fact but a partial resolution of the labeling dispute: B's own Bayesian update (3-of-4 analysts independently read the series as Dallas being the ~0.70-0.80 favorite) and B's d7 (point-spread magnitude matching my own spread-widening proxy) both corroborate the direction and rough magnitude I already assumed, nudging my point estimate from 0.73 to 0.75. D's critique of autocorrelation-inflated convergence is a valid partial offset — it reminds me that 'three analysts agree' is not fully independent confirmation if they're all anchoring on the same ambiguous scale/ordering convention, so I don't move as far as B's 0.75-weight update alone would suggest. A's home-field regression insignificance (p=0.775) doesn't move my probability at all, but it reinforces my core positioning thesis: since home-field itself isn't a reliable standalone driver in this sample, the market price (not an independent fundamental home-field argument) should dominate, which is exactly the 'it's priced in' framing I already held. For MY specific mandate (market positioning/crowding), nothing here changes the core read: the implied probability band (0.70-0.80) is tightly clustered (d2: sd=0.034 over 118 prints) and has been stable for days, meaning even with the direction now better-corroborated, there is still limited incremental tradeable edge in a 'Dallas wins' bet at current implied prices — the edge, if any, would have come from resolving the labeling ambiguity itself before the committee's convergence discussion closed it, not from the fundamental thesis. Crowding remains HIGH: a settled, low-variance, multi-day-flat price with multiple analysts converging on the same read is a classic 'priced-in' signature, not a mispricing. Base rate (0.70 for a ~5-6pt home favorite) sits almost exactly at my updated estimate, which itself confirms there's little divergence from base rate left to exploit. FALSIFICATION (updated): if the Kalshi KXNFLGAME-26OCT08TBDAL-DAL YES price trades below 0.60 or above 0.85 at any point 10/6-10/9, this positioning thesis (settled ~0.70-0.80 price, minimal edge) is falsified in either direction.

• +0.03 d6: Kalshi DAL-contract win probability over last 9 ticks (2026-09-29) ranges 0.66-0.77, trending up to 0.765/0.77 late in the week (A)
• +0.02 d2: 118 highly stable prints at 0.195 through 10/3-10/4, read as the complementary/TB-side price implying DAL ~0.80 — a large, low-variance series corroborating the same direction as A's smaller early-week series (C)
• +0.02 Cross-analyst convergence: 3 of 4 analysts (A, C, and B's own revised posterior) independently land on DAL-favored direction; B explicitly updates P(DAL-underdog reading) down to 0.25 after accounting for this consensus (B)
• +0.00 s5 (A) and s4 (B): two independent HAC regressions both find home-field status alone is NOT significant for Dallas (beta=1.33, p=.775 on win-margin framing; beta=-5.09, p=.245 on scoring margin) — this neither confirms nor refutes the market-level estimate, it just reallocates the source of edge from 'home field' to 'team quality/market price', so it leaves my market-centered estimate unchanged (A/B)

BASE RATE: unconditional NFL home-win rate ≈0.57; for a market-implied home favorite in the ~65-80% range, historical calibration of similar-tier favorites is roughly 0.68-0.72 (C's recalled reference class, UNVERIFIED by a tool, so treated as soft prior only). What changed my mind: My own standing objection — that the series' entity/direction labeling (d1/d2/d6-d8 across analysts) is not confirmed by metadata — is unresolved and remains the single largest source of uncertainty; I do not concede that cross-analyst convergence constitutes verification, only that it is a weak Bayesian update over which of two mutually exclusive labeling hypotheses is more likely true. Three independent readings (A, C, and B's self-correction) landing on 'Dallas is a market-implied favorite in the 0.66-0.80 range' is more probable under the hypothesis that this labeling is correct than under the hypothesis that all three independently made the same labeling error, so I give this modest weight (+0.02 for the consensus itself, beyond what each individual series contributes). A's d6 and C's d2 are two separately-sourced series (different n, different time windows) both pointing the same direction, which is mild corroboration not available to me when I wrote my original thesis — I update for this (+0.03, +0.02). The two null home-field regressions (A's s5, B's s4) are OBSERVED results I did not have before, but they are evidentially inert for my estimate: they tell me home-field advantage specifically is not doing work in this sample, which is compatible with (not contradictory to) a market price that reflects team-quality differential instead. I assign delta=0 because this doesn't move my probability of the game outcome, only my understanding of mechanism — and I flag that neither regression was tested for the autocorrelation/effective-N problem I raised for s3 in my own original evidence, so I cannot even be confident these p-values are well-calibrated. What I still do NOT concede: no analyst produced an actual confirmed contract-ID-to-series mapping (a metadata/schema lookup) — the entire update rests on analyst agreement about an ambiguous label, not verification. This is a meaningfully weaker form of evidence than a ground-truth check, so I cap my new estimate well below the market-implied 0.69-0.80 band and keep confidence moderate rather than high. I move from 0.58 to 0.65 — roughly halfway between the base rate and the converged-upon market band — reflecting partial but incomplete trust in the consensus reading.

SYNTHESIS: The committee's calibration-weighted pool lands at 0.67; I set my consensus at 0.65, modestly below the pool, because the pool's convergence is less independent than it appears. Three of four analysts (A, C, and B's self-correction) read an ambiguous, unlabeled Kalshi-derived series as 'Dallas priced as a 0.66-0.80 favorite,' but B and C's respective series (B's d1, C's d2) are very likely the *same raw 118-observation series read in opposite directions*, and A's d6 is a smaller, separate 9-observation series. Collapsing duplicated evidence: there are really only two quasi-independent empirical threads here -- (1) one ambiguous high-n market price series whose team-side label is unconfirmed, and (2) two overlapping null findings that home-field advantage alone has no significant effect on Dallas's outcomes/margins this season (A's s5, B's s4 -- same test family, treated as one line of evidence, not two). D's autocorrelation/effective-N critique (s3) is the most methodologically independent contribution and is why I weight D highest among the panel (0.32) despite D also partially deferring to the same convergence logic. BASE RATE: Unconditional NFL home-win rate ~0.57; home favorites in the market-implied 60-70% tier, or point-spread favorites of 5-6 points, win historically in the ~0.68-0.72 range per C's (unverified, from-memory) reference class. My update starts from this ~0.60-0.65 blended base rate and moves modestly toward the market-implied band (0.66-0.80), landing at 0.65 -- below the committee's 0.67 and well below C's 0.75, reflecting three discounts the committee underweighted: (a) zero tool-confirmed ticker metadata resolving the central labeling dispute, (b) a 4-day gap between the last observed data (2026-10-04) and kickoff (2026-10-09) with no injury-news coverage, and (c) all four analysts' own calibration track records in this segment are weak (accuracy 0.29-0.40, small samples), meaning the pooling weights themselves carry real estimation error. TRADEABILITY: This is a genuinely crowded, largely-priced-in setup if the market-favorite reading is correct (C's point, which I accept) -- a tightly clustered, low-variance, multi-day-stable price with multiple analysts converging on the same read is the classic signature of limited incremental edge, not mispricing. I do NOT recommend a conviction long-DAL position at current committee-implied levels (0.65-0.77) because the expected edge over a correctly-priced market is thin and the downside tail (the labeling-inversion scenario, where DAL is actually priced ~0.20) is large and currently un-falsifiable with available tools. The only clean trade I'd authorize: (1) first verify the Kalshi ticker-to-contract mapping via a direct metadata/schema lookup (not available in this round) before sizing any position; (2) conditional on verification confirming DAL is priced in the 0.65-0.80 band, a small tactical long-DAL-YES position is justifiable only if the contract trades below ~0.62 (i.e., below my updated fair value with a margin of safety), sized small given crowding; (3) if verification instead confirms the inverted reading, this entire thesis flips and a long-TB position would be warranted instead. Absent verification, I treat this as directionally informative but not independently tradeable with confidence -- the position size that respects the unresolved identification risk is near zero. OBSERVED: two distinct Kalshi-adjacent price series (9-obs early-week, 118-obs late and stable) with no confirmed team-label; two null HAC home-field regressions; one near-zero-power influence test. INFERRED: the two main series likely represent the same contract's opposing legs; analyst convergence provides weak (not confirmatory) evidence for the 'DAL favorite' labeling. MODELED: calibration-weighted log-odds pooling (committee=0.67); HAC regressions; leave-one-out influence test; spread-to-probability mapping. PREDICTED: P(DAL beats TB at home, 2026-10-09) = 0.65, 90% CI [0.52, 0.77]. UNCERTAIN: true contract-to-team labeling; independence of the analyst convergence; pre-kickoff injury news; well-calibratedness of all four analysts given small, weak-accuracy track records in this segment.

Consensus 67% · interval 52% to 77%